<DOC>
	<DOCNO>NCT00825994</DOCNO>
	<brief_summary>The purpose study determine eight-week intervention omega-3 fatty acid significantly reduce depressive symptom symptomatic peri- postmenopausal woman . We hypothesize eight-week trial omega-3 fatty acid promote significant improvement depression symptom peri- postmenopausal woman .</brief_summary>
	<brief_title>Omega-3 Peri- Postmenopausal Depression</brief_title>
	<detailed_description>The perimenopause commonly define time hormonal fluctuation typically occur woman 40-55 year age change menstrual pattern ( Soares et al . 2001 ; Cohen et al . 2003 ) . Women particularly high risk depressive symptom perimenopause , demonstrate epidemiological data support high risk perimenopause ( 15-18 % prevalence rate ) premenopause ( 8-12 % ) ( Bromberger et al. , 2003 ) . Women may especially vulnerable depressive symptom perimenopause due decline level estrogen . Estrogen interact neurotransmitter serotonin receptor expression , may antidepressant effect ; estrogen monotherapy may alleviate depressive symptom associate improved quality life ( Soares et al . 2001 ; Cohen et al. , 2003 ) . Of great practical clinical importance , hormone replacement therapy become increasingly controversial light finding Women 's Health Initiative study ( Roussouw et al.,2002 ) . Soares et al . ( 2003 ) find woman perimenopausal postmenopausal depression respond well treatment citalopram alone combination estrogen . Venlafaxine , mirtazapine , escitalopram , duloxetine appear efficacious open pilot study perimenopausal depression ( Ladd et al. , 2005 , Joffe et al . 2001 ; Freeman et al. , 2006 ; Joffe et al. , 2007 ) . However , antidepressant medication may associate significant side effect . Clinicians , researcher , patient seek alternative treatment menopausal-related emotional physical symptom . Investigators demonstrate promising result omega-3 fatty acid treatment intervention MDD ( Major Depressive Disorder ) . Overall , treatment data MDD support role EPA ( eicosapentaenoic acid ) DHA ( docosahexaenoic acid ) combination EPA omega-3 fatty acid intervention . The majority publish trial utilized EPA DHA combination EPA alone demonstrate significant benefit MDD . Omega-3 fatty acid ( sometimes abbreviate n-3 fatty acid ) nutritional compound widely establish health benefit . Omega-3 fatty acid polyunsaturated fatty acid . The American Psychiatric Association 's ( APA ) Committee Research Psychiatric Treatments conduct meta-analysis placebo-controlled treatment study MDD bipolar depression find significant benefit omega-3 fatty acid ( Freeman et al. , 2006 ) . Treatment estrogen compound , oral contraceptive pill oral estrogen replacement therapy , show increase level DHA woman , theoretically upregulation DHA synthesis dietary precursor ( Giltay et al. , 2004 ) . Increased EPA DHA plasma due hormone replacement therapy propose account antidepressant effect ( Sumino et al. , 2003 ) . Should decline endogenous estrogen level , therefore , low amount omega-3 fatty acid available brain , supplementation perimenopause may particular importance .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Women age 40 old peri postmenopausal period , define Soules et al . 2001 Meet criterion Major Depressive Disorder MINI ( MiniInternational Neuropsychiatric Interview ) Score 18 great MADRS ( MontgomeryAsberg Depression Rating Scale ) screen visit Do meet criterion placebo response placebo runin phase ; placebo response define &gt; 50 % decrease MADRS screen end placebo runin phase Willing receive treatment outpatient basis Presence general good health Currently pregnant , try conceive , breastfeed Treatment antidepressant medication currently past 1 month Treatment hormone replacement therapy currently past 1 month Treatment Omega3 supplement currently past 1 month Use birth control pills currently past 1 month Presence suicidal ideation Meet criterion current within past month panic disorder , obsessive compulsive disorder ( OCD ) , psychosis , mania hypomania , assess MINI Diagnosis treatment resistant Major Depressive Disorder , define patient treat two therapeutic course antidepressant medication without remission symptom current episode depression , assess MINI Any medical condition would make participation study unsafe , determined investigator Presence know allergy fish fish oil would put participant risk , determine study investigator</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>menopause</keyword>
	<keyword>perimenopause</keyword>
	<keyword>postmenopause</keyword>
	<keyword>depression</keyword>
	<keyword>mood</keyword>
	<keyword>sleep</keyword>
	<keyword>hot flash</keyword>
</DOC>